Platelet reactivity, inflammation and endothelial dysfunction during and after exacerbation in chronic obstructive pulmonary disease (COPD) patients

Completed

• Conditions: Chronic Obstructive Pulmonary Disease; COPD; 10011082; 10003216

• Registration Number: NL-OMON46302
• Lead Sponsor: Gelre Ziekenhuizen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 76

Inclusion Criteria

* Acute exacerbation of COPD, defined as an as an acute worsening of respiratory symptoms that results in additional therapy (COPD Gold 2018)
* >40 years oud
* Moderate to severe (>Gold 2) airflow limitation detected by spirometry (FEV1/FVC ratio < 70%, FEV1 < 80%) and clinical diagnosis of COPD confirmed by a pulmonologist.
* Current or former smoker, with *10 pack years of smoking

Exclusion Criteria

* Suspected or proven alternative diagnosis for the acute deterioration in symptoms such as pneumonia, pulmonary embolism or heart failure
* Use of anti-coagulants, aspirin or other platelet function inhibitors
* Use of statins or ACE inhibitors
* Concomitant diagnosis of asthma or other respiratory disease
* Diagnosis of hepatic and/or renal failure
* Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, systemic lupus erythematous (SLE), diabetes mellitus (DM)
* Malignancies (excluding basal cell carcinoma of the skin)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study outcome is platelet activation/reactivity, expressed as the<br /><br>membrane expression of the platelet activation markers CD62P (P-selectin) and<br /><br>activation of integrin *IIb*3, following ex vivo stimulation with platelet<br /><br>agonists ADP, CRP and TRAP.</p><br>